

## REFERENCES

- Abdul-Aziz, M.H., Sulaiman, H., Mat-Nor, M.-B., Rai, V., Wong, K.K., Hasan, M.S., et al., 2016. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. *Intensive Care Medicine*, **42**: 1535–1545.
- Aboulatta, L., Sugita, H., Wakabayashi, H., Noma, H., and Sasaki, T., 2020. Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: A systematic review and meta-analysis. *International Journal of Infectious Diseases*, **98**: 41–50.
- Adedeji, W.A., 2016. THE TREASURE CALLED ANTIBIOTICS. *Annals of Ibadan Postgraduate Medicine*, **14**: 56–57.
- Ahmed, N., Jen, S.-P., Altshuler, D., Papadopoulos, J., Pham, V.P., and Dubrovskaya, Y., 2020. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients. *Journal of Intensive Care Medicine*, **35**: 763–771.
- Al-Shaer, Mohammad H., Alghamdi, W.A., Graham, E., and Peloquin, C.A., 2020. Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples. *Therapeutic Drug Monitoring*, **42**: 129–132.
- Al-Shaer, Mohammad H, Rubido, E., Cherabuddi, K., Venugopalan, V., Klinker, K., and Peloquin, C., 2020. Early therapeutic monitoring of  $\beta$ -lactams and associated therapy outcomes in critically ill patients. *Journal of Antimicrobial Chemotherapy*, **75**: 3644–3651.
- Ammar, M. and Abdalla, W., 2018. Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia. *Saudi Journal of Anaesthesia*, **12**: 89.
- An, G., Creech, C.B., Wu, N., Nation, R.L., Gu, K., Nalbant, D., et al., 2023. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis. *Antimicrobial Agents and Chemotherapy*, **67**: e0131222.
- AstraZeneca, 2013. MERREM I.V. (meropenem for injection), Prescribing Information. *FDA Center for Drug Evaluation and Research*, .

- Bahlis, L.F., Diogo, L.P., and Fuchs, S.C., 2021. Charlson Comorbidity Index and other predictors of in-hospital mortality among adults with community-acquired pneumonia. *Jornal Brasileiro De Pneumologia: Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisiologia*, **47**: e20200257.
- Balli, S., Shumway, K.R., and Sharan, S., 2022. *Physiology, Fever*, StatPearls [Internet]. StatPearls Publishing.
- Baran, A., Kwiatkowska, A., and Potocki, L., 2023. Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race. *International Journal of Molecular Sciences*, **24**: 5777.
- Bébéar, C.M. and Pereyre, S., 2005. Mechanisms of drug resistance in *Mycoplasma pneumoniae*. *Current Drug Targets. Infectious Disorders*, **5**: 263–271.
- Bilgrami, I., Roberts, J.A., Wallis, S.C., Thomas, J., Davis, J., Fowler, S., et al., 2010. Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. *Antimicrobial Agents and Chemotherapy*, **54**: 2974–2978.
- Blassmann, U., Roehr, A.C., Frey, O.R., Vetter-Kerkhoff, C., Thon, N., Hope, W., et al., 2016. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. *Critical Care (London, England)*, **20**: 343.
- Blázquez, J., Couce, A., Rodríguez-Beltrán, J., and Rodríguez-Rojas, A., 2012. Antimicrobials as promoters of genetic variation. *Current Opinion in Microbiology*, **15**: 561–569.
- Bolus, J. and Turner, R.B., 2016. Prolonged-Infusion Dosing of Beta-Lactam Antibiotics.
- C Reygaert, W., 2018. An overview of the antimicrobial resistance mechanisms of bacteria. *AIMS Microbiology*, **4**: 482–501.
- Capuzzo, M., Valpondi, V., Sgarbi, A., Bortolazzi, S., Pavoni, V., Gilli, G., et al., 2000. Validation of severity scoring systems SAPS II and APACHE II in a single-center population. *Intensive Care Medicine*, **26**: 1779–1785.

- Charlson, M.E., Pompei, P., Ales, K.L., and MacKenzie, C.R., 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of Chronic Diseases*, **40**: 373–383.
- Chen, I.H., Martin, E.K., Nicolau, D.P., and Kuti, J.L., 2020. Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. *Clinical Therapeutics*, **42**: 606–613.
- Chi, S.Y., Kim, T.O., Park, C.W., Yu, J.Y., Lee, B., Lee, H.S., et al., 2012. Bacterial pathogens of ventilator associated pneumonia in a tertiary referral hospital. *Tuberculosis and Respiratory Diseases*, **73**: 32–37.
- Chytra, I., Stepan, M., Benes, J., Pelnar, P., Zidkova, A., Bergerova, T., et al., 2012. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. *Critical Care*, **16**: R113.
- Cillóniz, C., Ewig, S., Ferrer, M., Polverino, E., Gabarrús, A., Puig de la Bellacasa, J., et al., 2011. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. *Critical Care (London, England)*, **15**: R209.
- Combes, A., Figliolini, C., Trouillet, J.-L., Kassis, N., Wolff, M., Gibert, C., et al., 2002. Incidence and Outcome of Polymicrobial Ventilator-Associated Pneumonia. *Chest*, **121**: 1618–1623.
- Cong, Y., Yang, S., and Rao, X., 2020. Vancomycin resistant *Staphylococcus aureus* infections: A review of case updating and clinical features. *Journal of Advanced Research*, **21**: 169–176.
- Craig, W.A., 1997. The pharmacology of meropenem, a new carbapenem antibiotic. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **24 Suppl 2**: S266-275.
- Crandon, J.L., Ariano, R.E., Zelenitsky, S.A., Nicasio, A.M., Kuti, J.L., and Nicolau, D.P., 2011. Optimization of meropenem dosage in the critically ill population based on renal function. *Intensive Care Medicine*, **37**: 632–638.
- Cunha, B.A., 1998. Meropenem in elderly and renally impaired patients. *International Journal of Antimicrobial Agents*, **10**: 107–117.

- Cunha, B.A. and Cunha, C.B. (Editor), 2020. *Antibiotic Essentials*, Seventeenth edition. ed. Jaypee Brothers Medical Publishers, New Delhi, India.
- Czajkowski, K., Broś-Konopielko, M., and Teliga-Czajkowska, J., 2021. Urinary tract infection in women. *Przegląd Menopauzalny = Menopause Review*, **20**: 40–47.
- Dadgostar, P., 2019. Antimicrobial Resistance: Implications and Costs. *Infection and Drug Resistance*, **Volume 12**: 3903–3910.
- Dandekar, P.K., Maglio, D., Sutherland, C.A., Nightingale, C.H., and Nicolau, D.P., 2003. Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion. *Pharmacotherapy*, **23**: 988–991.
- Dhillon, S., 2018. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. *Drugs*, **78**: 1259–1270.
- Drusano, G.L., 2003. Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents. *Clinical Infectious Diseases*, **36**: S42–S50.
- Falagas, M.E., Mourtzoukou, E.G., and Vardakas, K.Z., 2007. Sex differences in the incidence and severity of respiratory tract infections. *Respiratory Medicine*, **101**: 1845–1863.
- Fawaz, S., Barton, S., Whitney, L., Swinden, J., and Nabhani-Gebara, S., 2019. Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion. *Hospital Pharmacy*, **54**: 190–196.
- Felton, T.W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., et al., 2013. Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*, **57**: 5811–5819.
- Fish, D.N., 2006. Meropenem in the treatment of complicated skin and soft tissue infections. *Therapeutics and Clinical Risk Management*, **2**: 401–415.
- Florea, N.R., Kotapati, S., Kutti, J.L., Geissler, E.C., Nightingale, C.H., and Nicolau, D.P., 2003. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. *American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists*, **60**: 2321–2327.

- Frippiat, F., Musuamba, F.T., Seidel, L., Albert, A., Denooz, R., Charlier, C., et al., 2015. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. *Journal of Antimicrobial Chemotherapy*, **70**: 207–216.
- Gaurav, A., Bakht, P., Saini, M., Pandey, S., and Pathania, R., 2023. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. *Microbiology (Reading, England)*, **169**: 001333.
- Ghoshal, L., Nandi, S., Sarkar, A., and Das, S., 2015. Acute generalized exanthematous pustulosis due to meropenem: An unusual side effect of a commonly used drug. *Indian Dermatology Online Journal*, **6**: 446–448.
- Gillespie, E.L., Kuti, J.L., and Nicolau, D.P., 2005. Pharmacodynamics of antimicrobials: treatment optimisation. *Expert Opinion on Drug Metabolism & Toxicology*, **1**: 351–361.
- Gil-Serrano, J., Cardona, V., Luengo, O., Guilarte, M., Sala-Cunill, A., Galvan-Blasco, P., et al., 2019. Anaphylactic shock to meropenem with ertapenem tolerance: A case report. *The Journal of Allergy and Clinical Immunology. In Practice*, **7**: 2057–2058.
- Haj-Darrah, R., Leung, E., and Zvonar, R., 2017. Should Prolonged Infusion of  $\beta$ -Lactams Become Standard of Practice? *The Canadian Journal of Hospital Pharmacy*, **70**: .
- Hanberg, P., Lund, A., Søballe, K., and Bue, M., 2019. Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis: An animal study. *Bone & Joint Research*, **8**: 313–322.
- Headley, J., Theriault, R., and Smith, T.L., 1992. Independent validation of APACHE II severity of illness score for predicting mortality in patients with breast cancer admitted to the intensive care unit. *Cancer*, **70**: 497–503.
- Henig, O. and Kaye, K.S., 2017. Bacterial Pneumonia in Older Adults. *Infectious Disease Clinics of North America*, **31**: 689–713.
- Heron, M., 2015. Deaths : Leading Causes for 2011. *National Vital Statistics Report*, **64**: .

- Hooper, D.C. and Jacoby, G.A., 2016. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. *Cold Spring Harbor Perspectives in Medicine*, **6**: a025320.
- Huang, R., Cai, G.-Q., Zhang, J.-H., Liu, F.-X., Ma, J.-Q., Liu, H., et al., 2017. Meropenem-induced immune thrombocytopenia and the diagnostic process of laboratory testing: MEROPENEM-INDUCED DITP. *Transfusion*, **57**: 2715–2719.
- Indrawaty, S., Sosialine, E., and Umar, F., 2011. Pedoman Interpretasi Data Klinik.
- Itabashi, S., 2007. [Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia]. *The Japanese Journal of Antibiotics*, **60**: 161–170.
- Ito, A., Ishida, T., Tachibana, H., Tokumasu, H., Yamazaki, A., and Washio, Y., 2019. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis. *Scientific Reports*, **9**: 18406.
- James, M.T., Quan, H., Tonelli, M., Manns, B.J., Faris, P., Laupland, K.B., et al., 2009. CKD and Risk of Hospitalization and Death With Pneumonia. *American Journal of Kidney Diseases*, **54**: 24–32.
- Kalil, A.C., Metersky, M.L., Klompas, M., Muscedere, J., Sweeney, D.A., Palmer, L.B., et al., 2016. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*, **63**: e61–e111.
- Katchanov, J., Kreuels, B., Maurer, F.P., Wöstmann, K., Jochum, J., König, C., et al., 2017. Risk factors for excessively prolonged meropenem use in the intensive care setting: a case-control study. *BMC Infectious Diseases*, **17**: 131.
- Kaufman, D.P., Basit, H., and Knohl, S.J., 2024. Physiology, Glomerular Filtration Rate, in: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Kelsey, J.L., Whittemore, A.S., Evans, A.S., and Thompson (Editor), 1996. *Methods in Observational Epidemiology*, 2nd ed. ed, Monographs in epidemiology and biostatistics. Oxford University Press, New York.

- Kıran, P., Nadir, Y., and Gencer, S., 2023. Clinical efficacy and safety of prolonged versus intermittent administration of antipseudomonal beta-lactam antibiotics in adults with severe acute infections: A meta-analysis of randomized controlled trials. *Journal of Infection and Chemotherapy*, **29**: 855–862.
- Knaus, W.A., Draper, E.A., Wagner, D.P., and Zimmerman, J.E., 1985. APACHE II: a severity of disease classification system. *Critical Care Medicine*, **13**: 818–829.
- Kollef, M.H., Chastre, J., Clavel, M., Restrepo, M.I., Michiels, B., Kaniga, K., et al., 2012. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. *Critical Care (London, England)*, **16**: R218.
- Kondo, Y., Ota, K., Imura, H., Hara, N., and Shime, N., 2020. Prolonged versus intermittent  $\beta$ -lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials. *Journal of Intensive Care*, **8**: 77.
- Koomanachai, P., Bulik, C.C., Kuti, J.L., and Nicolau, D.P., 2010. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. *Clinical Therapeutics*, **32**: 766–779.
- Kumagai, S., Ishida, T., Tachibana, H., Ito, A., Ito, Y., and Hashimoto, T., 2016. Polybacterial aetiology and outcomes in patients with community-acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease*, **20**: 129–135.
- Leroy, A., Fillastre, J.P., Borsa-Lebas, F., Etienne, I., and Humbert, G., 1992. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. *Antimicrobial Agents and Chemotherapy*, **36**: 2794–2798.
- Lessard, J.-J., Caron, E., Schérer, H., Forest, J.-M., and Leclair, G., 2020. Compatibility of Y-Site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. *Hospital Pharmacy*, **55**: 332–337.
- Liebchen, U., Dorn, C., Kees, M., Schiesser, S., Hitzenbichler, F., Kees, F., et al., 2020. Comment on “Meropenem, Cefepime, and Piperacillin Protein



Binding in Patient Samples.” *Therapeutic Drug Monitoring*, **42**: 909–910.

Lim, W.S., 2022. Pneumonia—Overview, in: *Encyclopedia of Respiratory Medicine*. Elsevier, pages 185–197.

Llor, C. and Bjerrum, L., 2014. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Therapeutic Advances in Drug Safety*, **5**: 229–241.

Lodise, T.P., Lomaestro, B.M., and Drusano, G.L., 2006. Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on  $\beta$ -Lactam Antibiotics: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*, **26**: 1320–1332.

Lokhandwala, A., Patel, P., Isaak, A.K., Faizan Yousaf, R., Maslamani, A.N.J., Khalil, S.K., et al., 2023. Comparison of the Effectiveness of Prolonged Infusion and Intermittent Infusion of Meropenem in Patients With Sepsis: A Meta-Analysis. *Cureus*, .

Louie, A., Liu, W., VanGuilder, M., Neely, M.N., Schumitzky, A., Jelliffe, R., et al., 2015. Combination treatment with meropenem plus levofloxacin is synergistic against *Pseudomonas aeruginosa* infection in a murine model of pneumonia. *The Journal of Infectious Diseases*, **211**: 1326–1333.

Lyu, Y., Yang, Y., Li, X., Peng, M., He, X., Zhang, P., et al., 2017. Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study. *Therapeutics and Clinical Risk Management*, **Volume 14**: 31–37.

MacVane, S.H., Kuti, J.L., and Nicolau, D.P., 2014. Prolonging  $\beta$ -lactam infusion: A review of the rationale and evidence, and guidance for implementation. *International Journal of Antimicrobial Agents*, **43**: 105–113.

Mancuso, G., Midiri, A., Gerace, E., and Biondo, C., 2021. Bacterial Antibiotic Resistance: The Most Critical Pathogens. *Pathogens (Basel, Switzerland)*, **10**: 1310.

McEvoy, G.K. and American Society of Health System Pharmacists (Editor), 2017. *Handbook on Injectable Drugs: ASHP’s Guide to IV Compatibility and Stability*, 19th edition. ed. ASHP, Bethesda, MD.



- Miki, T., Nanri, A., Mizoue, T., Goto, A., Noda, M., Sawada, N., et al., 2023. Association of body mass index and weight change with pneumonia mortality in a Japanese population: Japan Public Health Center-based Prospective Study. *International Journal of Obesity* (2005), **47**: 479–486.
- Moehring, R. and Sarubbi, C., 2023. Prolonged infusions of beta-lactam antibiotics.
- Mosichuk, A.P., Smith, J.S., Tatarniuk, D.M., Troy, J.R., and Kreuder, A.J., 2021. Meropenem Administered via Intravenous Regional Limb Perfusion for Orthopedic Sepsis in Horses: A Clinical Retrospective Study. *Frontiers in Veterinary Science*, **8**: 629627.
- Murray, C.J.L., Ikuta, K.S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., et al., 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*, **399**: 629–655.
- Negi, A., Anand, M., Singh, A., Kumar, A., Sahu, C., and Prasad, K.N., 2017. Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of *Pseudomonas aeruginosa* in a Tertiary Care Hospital of North India. *Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine*, **21**: 703–706.
- Nie, W., Zhang, Y., Jee, S.H., Jung, K.J., Li, B., and Xiu, Q., 2014. Obesity survival paradox in pneumonia: a meta-analysis. *BMC Medicine*, **12**: 61.
- Oka, S., Shiragami, H., and Nohgawa, M., 2015. Intravascular hemolytic anemia in a patient with antibodies related to meropenem. *Internal Medicine (Tokyo, Japan)*, **54**: 1291–1295.
- Orimo, H., Ito, H., Suzuki, T., Araki, A., Hosoi, T., and Sawabe, M., 2006. Reviewing the definition of “elderly.” *Geriatrics & Gerontology International*, **6**: 149–158.
- Ota, K., Kaku, N., and Yanagihara, K., 2020. Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing *Klebsiella pneumoniae* mouse model of pneumonia. *Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy*, **26**: 1237–1243.
- Paquet, P., Jacob, E., Damas, P., and Piérard, G.E., 2002. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell’s syndrome) after putative  $\beta$ -

lactam cross-reactivity: Case report and scrutiny of antibiotic imputability: *Critical Care Medicine*, **30**: 2580–2583.

Pasquau-Liaño, J., 2022. Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program. *Revista Española de Quimioterapia*, **35**: 102–107.

Patel, N., Scheetz, M.H., Drusano, G.L., and Lodise, T.P., 2010. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. *Antimicrobial Agents and Chemotherapy*, **54**: 460–465.

Pesta, M., Datler, P., Scheriau, G., Wohlrab, P., Eberl, S., Lackner, E., et al., 2023. “Comparison of antibiotic protein binding in human plasma vs. rabbit plasma”, , *preprint*, . Pharmacology and Toxicology.

Prados-Castaño, M., Piñero-Saavedra, M., Leguísamo-Milla, S., Ortega-Camarero, M., and Vega-Rioja, A., 2015. DRESS syndrome induced by meropenem. *Allergologia Et Immunopathologia*, **43**: 233–235.

Prestinaci, F., Pezzotti, P., and Pantosti, A., 2015. Antimicrobial resistance: a global multifaceted phenomenon. *Pathogens and Global Health*, **109**: 309–318.

Pulingam, T., Parumasivam, T., Gazzali, A.M., Sulaiman, A.M., Chee, J.Y., Lakshmanan, M., et al., 2022. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. *European Journal of Pharmaceutical Sciences*, **170**: 106103.

Quan, H., Li, B., Couris, C.M., Fushimi, K., Graham, P., Hider, P., et al., 2011. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *American Journal of Epidemiology*, **173**: 676–682.

Raghubanshi, B.R. and Karki, B.M.S., 2020. Bacteriology of Sputum Samples: A Descriptive Cross-sectional Study in a Tertiary Care Hospital. *JNMA; journal of the Nepal Medical Association*, **58**: 24–28.

Regunath, H. and Oba, Y., 2022. *Community-Acquired Pneumonia*, StatPearls [Internet]. StatPearls Publishing.

- Rodvold, K.A., George, J.M., and Yoo, L., 2011. Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid: Focus on Antibacterial Agents. *Clinical Pharmacokinetics*, **50**: 637–664.
- Sabaz, M.S. and Aşar, S., 2021. Association of Charlson Comorbidity and Pneumonia Severity Indices with Mortality in Patients with Coronavirus Disease-2019 in the Intensive Care Unit. *Turkish Journal of Intensive Care*, **19**: 33–41.
- Salmon-Rousseau, A., Martins, C., Blot, M., Buisson, M., Mahy, S., Chavanet, P., et al., 2020. Comparative review of imipenem/cilastatin versus meropenem. *Medecine Et Maladies Infectieuses*, **50**: 316–322.
- Sameed, M., Nwaiser, C., Bhandari, P., and Schmalzle, S.A., 2019. Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. *BMJ case reports*, **12**: e230144.
- Sauvage, E., Derouaux, A., Fraipont, C., Joris, M., Herman, R., Rocaboy, M., et al., 2014. Crystal structure of penicillin-binding protein 3 (PBP3) from *Escherichia coli*. *PloS One*, **9**: e98042.
- Scholar, E., 2007. Meropenem, in: *xPharm: The Comprehensive Pharmacology Reference*. Elsevier, pages 1–5.
- Shebl, E. and Gulick, P.G., 2022. *Nosocomial Pneumonia*, StatPearls [Internet]. StatPearls Publishing.
- Stein, S.M. (Editor), 2015. *Boh's Pharmacy Practice Manual: A Guide to the Clinical Experience*, Fourth edition. ed. Wolters Kluwer Health, Philadelphia.
- Su, G., Xu, H., Marrone, G., Lindholm, B., Wen, Z., Liu, X., et al., 2017. Chronic kidney disease is associated with poorer in-hospital outcomes in patients hospitalized with infections: Electronic record analysis from China. *Scientific Reports*, **7**: 11530.
- Suk, C., Hsu, S., Chen, C., Hsieh, H., Kuo, H., Hsu, Y., et al., 2019. Point of Care eGFR and the Prediction of Outcomes in Pneumonia. *Scientific Reports*, **9**: 8478.
- Turnidge, J.D., 1998. The Pharmacodynamics of  $\beta$ -Lactams. *Clinical Infectious Diseases*, **27**: 10–22.

- Van Tuyl, J.S., Jones, A.N., and Johnson, P.N., 2016. Meropenem-Induced Neutropenia in a Neonate. *The journal of pediatric pharmacology and therapeutics: JPPT: the official journal of PPAG*, **21**: 353–357.
- Vestby, L.K., Grønseth, T., Simm, R., and Nesse, L.L., 2020. Bacterial Biofilm and its Role in the Pathogenesis of Disease. *Antibiotics (Basel, Switzerland)*, **9**: 59.
- Wang, D., 2009. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant *Acinetobacter baumannii*. *International Journal of Antimicrobial Agents*, **33**: 290–291.
- World Health Organization, 2019. *2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline*. World Health Organization, Geneva.
- Xie, X., Xiang, B., Wu, Y., Zhao, Y., Wang, Q., and Jiang, X., 2018. Infant progressive colonic stenosis caused by antibiotic-related *Clostridium difficile* colitis - a case report and literature review. *BMC pediatrics*, **18**: 320.
- Yu, Z., Pang, X., Wu, X., Shan, C., and Jiang, S., 2018. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis. *PLOS ONE*, **13**: e0201667.
- Zapun, A., Contreras-Martel, C., and Vernet, T., 2008. Penicillin-binding proteins and  $\beta$ -lactam resistance. *FEMS Microbiology Reviews*, **32**: 361–385.
- Zembles, T.N., Schortemeyer, R., Kuhn, E.M., Bushee, G., Thompson, N.E., and Mitchell, M.L., 2021. Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients. *The journal of pediatric pharmacology and therapeutics: JPPT: the official journal of PPAG*, **26**: 187–193.
- Zhao, Y.-C., Zou, Y., Xiao, Y.-W., Wang, F., Zhang, B.-K., Xiang, D.-X., et al., 2022. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. *Infectious Diseases and Therapy*, **11**: 201–216.